首頁 > 市場調查報告書 > 製藥

神經疾病

偏頭痛市場規模、佔有率和成長分析：按療法、藥物類別、疾病嚴重程度、給藥途徑、分銷管道和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2091191

偏頭痛市場規模、佔有率和成長分析：按療法、藥物類別、疾病嚴重程度、給藥途徑、分銷管道和地區分類－2026-2033年產業預測

Bradykinesia Market Size, Share, and Growth Analysis, By Therapy Type, By Drug Class, By Disease Severity, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2026年07月08日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球運動遲緩市場價值為 26.3 億美元，預計到 2033 年將從 2025 年的 28 億美元成長至 45.6 億美元，在預測期（2026-2033 年）內複合年成長率為 6.3%。

全球運動遲緩市場由創新療法、診斷方法和數位化解決方案驅動，這些療法和解決方案旨在解決帕金森氏症及相關神經退化性疾病引起的運動障礙。人口老化以及運動障礙對醫療保健系統帶來的經濟負擔，推動了市場需求的成長，促使人們增加對有效療法的投資。穿戴式感測器技術結合人工智慧分析，能夠精準評估運動功能，進而及早調整多巴胺促效劑治療方案。這有助於改善患者預後並減少住院次數。諸如運動追蹤腕帶之類的工具展示了數據驅動策略如何顯著降低成本。此外，人工智慧和物聯網的融合實現了持續監測和個人化護理，使運動遲緩的管理重點從常規就診轉向以患者為中心的預防性方法。

全球運動遲緩症市場按治療類型、藥物類別、疾病嚴重程度、給藥途徑、分銷管道和地區進行細分。依治療類型分類，市場分為單藥治療、聯合治療和聯合治療。依藥物類別分類，市場分為左旋多巴、多巴胺促效劑、MAO-B抑制劑、COMT抑制劑、抗膽鹼能藥物和金剛烷胺。依疾病嚴重程度分類，市場分為「帕金森氏症早期」和「帕金森氏症晚期」。依給藥途徑分類，市場分為「口服」、「經皮吸收貼片」及「皮下注射」。依分銷管道分類，市場分為「醫院藥局」、「零售藥局」及「線上藥局」。依地區分類，市場分為「北美」、「歐洲」、「亞太」、「拉丁美洲」以及「中東和非洲」。

全球運動遲緩市場成長要素

65歲及以上老年人口的不斷成長，顯著推高了神經退化性疾病（尤其是以運動遲緩為特徵的帕金森氏症）的發生率。這一人口趨勢使得人們更需要先進的診斷工具、創新的治療策略以及全面的支持性護理服務來應對運動障礙。因此，醫療系統和護理人員更加重視早期檢測和綜合管理方案，而製造商也正在加速產品研發投入。隨著患者和醫療專業人員對帕金森氏症嚴重影響的認知不斷提高，人們對新療法的接受度也不斷提高，進一步推動了市場成長。

全球運動遲緩市場面臨的限制因素

全球運動遲緩症市場面臨許多限制因素，主要源自於主要藥物、深部腦部刺激療法和創新穿戴裝置的高成本，這些成本往往超出公營和私人保險公司的報銷限額。這種情況對患者和醫療專業人員造成了預算限制，阻礙了他們獲得有效的運動遲緩症治療。因此，製造商必須提供充分的臨床證據來證明高價的合理性，而支付方則要求進行全面的成本效益評估。這些持續不斷的談判導致引進週期延長、需求疲軟、市場滲透緩慢，最終阻礙了全球患者對新型治療方案的投資。

全球運動遲緩症（一種運動技能障礙）市場趨勢

全球運動遲緩症市場的一大趨勢是遠端醫療解決方案的整合，這使得患者更容易獲得專科護理。遠距神經科會診和數位化症狀追蹤的普及，使臨床醫生能夠即時評估運動變異性並據此調整治療方案。這項創新加強了醫療服務提供者、病患和看護者之間的協作，促進了更有效的學習與合作。減少就診次數和提高治療方案的依從性有助於改善運動障礙患者的生活品質。此外，持續的數據分析在維持病情長期穩定和促進預防性干預方面發揮著至關重要的作用。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

BIAL-Portela & Ca, SA
Acadia Pharmaceuticals Inc.
Amneal Pharmaceuticals, Inc.
Orion Corporation
Daiichi Sankyo Company, Limited
Wockhardt Limited
Par Pharmaceutical, Inc.
Salix Pharmaceuticals, Inc.
Aurobindo Pharma Limited
STADA Arzneimittel AG
EVER Pharma GmbH
Zambon SpA
Kyowa Kirin Co., Ltd.

結論與建議

簡介目錄

Product Code: SQMIG35I3104

Global Bradykinesia Market size was valued at USD 2.63 Billion in 2024 and is poised to grow from USD 2.8 Billion in 2025 to USD 4.56 Billion by 2033, growing at a CAGR of 6.3% during the forecast period (2026-2033).

The global bradykinesia market is centered on innovative therapies, diagnostics, and digital solutions addressing the movement difficulties associated with Parkinson's and related neurodegenerative disorders. Growing demand is fueled by an aging population, along with the financial strain that motor impairments impose on healthcare systems, prompting investments in effective interventions. Wearable sensor technology combined with AI analytics enhances precise assessments of motor function, enabling earlier adjustments to dopaminergic treatments which can improve patient outcomes and reduce hospitalization. Tools like motion-tracking wristbands demonstrate how data-driven strategies can lead to significant cost savings. Additionally, the integration of AI and IoT facilitates continuous monitoring and personalized care, shifting the focus from periodic clinic visits to proactive, patient-centered approaches in managing bradykinesia.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bradykinesia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bradykinesia Market Segments Analysis

The global bradykinesia market is segmented by therapy type, drug class, disease severity, route of administration, distribution channel and region. Based on therapy type, the market is segmented into Mono-Therapy, Combination Therapy and Triple Therapy. Based on drug class, the market is segmented into Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics and Amantadine. Based on disease severity, the market is segmented into Early-Stage Parkinson's and Advanced-Stage Parkinson's. Based on route of administration, the market is segmented into Oral, Transdermal Patch and Subcutaneous Infusion. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Bradykinesia Market

The rising population of individuals aged sixty-five and above significantly contributes to an increased incidence of neurodegenerative disorders, prominently featuring Parkinson's disease, where bradykinesia is a main symptom. This demographic trend escalates the need for advanced diagnostic tools, innovative treatment strategies, and enhanced supportive care services aimed at addressing movement impairments. Consequently, healthcare systems and caregivers are placing greater emphasis on early detection and comprehensive management plans, motivating manufacturers to broaden their product offerings and invest in research and development. As awareness of the disease's disruptive nature grows among patients and healthcare providers, the acceptance of new solutions increases, further fueling market growth.

Restraints in the Global Bradykinesia Market

The Global Bradykinesia market faces significant constraints, primarily due to the high costs associated with leading pharmaceuticals, deep brain stimulation procedures, and innovative wearable devices often exceeding reimbursement caps set by both public and private insurers. This situation leads to budgetary constraints for patients and healthcare providers, hindering access to effective treatments for bradykinesia. Consequently, manufacturers must present substantial clinical evidence to justify their premium pricing, while payors require comprehensive assessments of cost-effectiveness. This ongoing negotiation results in extended adoption cycles, weakening demand, slowing market penetration, and ultimately discouraging investment in new treatment solutions for patients across the globe.

Market Trends of the Global Bradykinesia Market

The Global Bradykinesia market is witnessing a significant trend driven by the integration of telehealth solutions, enhancing patient access to specialized care. With the rise of remote neurology consultations and digital symptom tracking, clinicians can evaluate motor fluctuations in real-time, allowing for timely adjustments to treatment plans. This innovation facilitates stronger engagement between healthcare providers, patients, and caregivers, fostering more effective learning and collaboration. The reduction in travel burdens and increased adherence to therapeutic protocols contribute to improved daily living for individuals with movement disorders. Additionally, continuous data insights play a crucial role in maintaining long-term disease stability and promoting proactive interventions.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Bradykinesia Market Size by Therapy Type & CAGR (2026-2033)

Market Overview
Mono-Therapy
Combination Therapy
Triple Therapy

Global Bradykinesia Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Levodopa
Dopamine Agonists
MAO-B Inhibitors
COMT Inhibitors
Anticholinergics
Amantadine

Global Bradykinesia Market Size by Disease Severity & CAGR (2026-2033)

Market Overview
Early-Stage Parkinson's
Advanced-Stage Parkinson's

Global Bradykinesia Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Transdermal Patch
Subcutaneous Infusion

Global Bradykinesia Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Bradykinesia Market Size & CAGR (2026-2033)

North America (Therapy Type, Drug Class, Disease Severity, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Therapy Type, Drug Class, Disease Severity, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Therapy Type, Drug Class, Disease Severity, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Therapy Type, Drug Class, Disease Severity, Route of Administration, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Therapy Type, Drug Class, Disease Severity, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

BIAL - Portela & Ca, S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acadia Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orion Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wockhardt Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Par Pharmaceutical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Salix Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
STADA Arzneimittel AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EVER Pharma GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zambon S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments